e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Matching-adjusted indirect comparison of benralizumab
versus
interleukin-5 inhibitors for the treatment of severe asthma: a systematic review
Arnaud Bourdin, Don Husereau, Nicolas Molinari, Sarowar Golam, Mohd Kashif Siddiqui, Leandro Lindner, Xiao Xu
Source:
Eur Respir J, 52 (5) 1801393; 10.1183/13993003.01393-2018
Journal Issue:
November
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Arnaud Bourdin, Don Husereau, Nicolas Molinari, Sarowar Golam, Mohd Kashif Siddiqui, Leandro Lindner, Xiao Xu. Matching-adjusted indirect comparison of benralizumab
versus
interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J, 52 (5) 1801393; 10.1183/13993003.01393-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Omalizumab in the real-world: systematic review of asthma control outcomes reported by patients
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study.
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Treatment of asthma above and beyond anti IgE: an update for the clinician The use of biologicals in asthma treatment
Source: International Congress 2018 – Difficult paediatric lung disease
Year: 2018
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
The association between adherence and outcomes in severe asthma: a systematic review
Source: International Congress 2019 – Long-term evaluation and control of airway diseases
Year: 2019
As needed therapies in mild to severe asthma: a systematic review and network meta-analysis
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
Indirect comparison of efficacy of dupilumab
versus
mepolizumab and omalizumab for severe type 2 asthma
Source: ERJ Open Res, 7 (3) 00306-2021; 10.1183/23120541.00306-2021
Year: 2021
The burden of exacerbations in mild asthma: a systematic review
Source: ERJ Open Res, 6 (3) 00359-2019; 10.1183/23120541.00359-2019
Year: 2020
Erdosteine is effective as a treatment for acute exacerbation of COPD: a systematic review of clinical trials
Source: International Congress 2017 – COPD management
Year: 2017
Subcutaneous anti-immunoglobulin E (Omalizumab) as a steroid-sparing agent in allergic asthma – a systematic review of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 665s
Year: 2006
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
Effectiveness of anti-IgE and anti-IL-5 treatment in step 5 asthma patients.
Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Year: 2018
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020
Year: 2020
Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Deprescribing montelukast in children with asthma: a systematic review
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept